All In Biotech

Drug Trial Radar · NCT06295731

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

A Phase 2/3, Randomized Study of Ordastobart (INBRX-106) Plus Pembrolizumab vs Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma Expressing PD-L1 (HexAgon-HN)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

May 14, 2024

Primary completion

Dec 2029

Study completion May 2031

Sponsor

Lead sponsor
Inhibrx Biosciences, IncIndustry
Sponsor type
Industry
First posted
Mar 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with recurrent or metastatic (R/M) HPV-positive Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) expressing PD-L1.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

Interventions

  • INBRX-106Drug

    INBRX-106 0.1 mg/kg by intravenous (IV) infusion, given every 3 weeks (QW3)

  • PembrolizumabDrug

    Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Objective Response Rate by investigator (ORRinv)Time frame: From randomization to progressive disease (PD) or death (up to 1 year)
  2. Phase 3: Progression-Free Survival by Investigator (PFSinv)Time frame: From randomization to PD or death (up to 4 years)
  3. Phase 3: Overall Survival (OS)Time frame: From randomization until death from any cause (up to 4 years)

Locations

89 sites in 13 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • Los Angeles Cancer Network (LACN)

    Los Angeles, California · Recruiting

  • Sutter Health

    Sacramento, California · Withdrawn

  • UC Davis

    Sacramento, California · Terminated

  • Medical Oncology Associates of San Diego

    San Diego, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

  • ChristianaCare Health Services

    Newark, Delaware · Active not recruiting

  • University of Florida UF Health Cancer Center

    Gainesville, Florida · Active not recruiting

  • The Oncology Institute of Hope & Innovation

    Miami, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Cleveland Clinic Florida, The Maroone Cancer Center

    Weston, Florida · Active not recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Active not recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University St. Louis

    St Louis, Missouri · Recruiting

  • Intermountain Health, St. Vincent Regional Hospital, Cancer Centers of Montana

    Billings, Montana · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Christus St. Vincent Regional Cancer Center

    Santa Fe, New Mexico · Recruiting

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina · Recruiting

  • Oklahoma University Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Active not recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • CHRISTUS Spohn Cancer Center

    Corpus Christi, Texas · Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Active not recruiting

  • University Hospital Brussels

    Jette, Belgium · Active not recruiting

  • Chu Ucl Namur Site De Sainte-Elisabeth

    Namur, Belgium · Active not recruiting

  • Vitaz

    Sint-Niklaas, Belgium · Active not recruiting

  • Antwerp University Hospital

    Edegem, Antwerp, Belgium · Active not recruiting

  • Multiprofile Hospital for Active Treatment - "Uni Hospital" Ltd, Medical Oncology Dept

    Panagyurishte, Bulgaria · Active not recruiting

  • Complex Oncological Center Plovdiv EOOD Dept of Med Oncology and Oncological Diseases in Hematology

    Plovdiv, Bulgaria · Active not recruiting

  • Uni Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD Clinic of Medical Oncology

    Sofia, Bulgaria · Active not recruiting

  • Multiprofile Hospital for Active Treatment Sveta Sofia, Department of Medical Oncology

    Sofia, Bulgaria · Active not recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Active not recruiting

  • Cenre Oscar Lambret

    Lille, France · Active not recruiting

  • Centre Leon Berard

    Lyon, France · Active not recruiting

  • CH Annecy Genevois

    Annecy, Epagny Metz Tessy, France · Active not recruiting

  • UNEOS-Hopital R.SCHUMAN

    Metz, Moselle, France · Active not recruiting

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.